Deutsche Bank Keeps Their Sell Rating on AstraZeneca (AZN)

Deutsche Bank analyst Emmanuel Papadakis maintained a Sell rating on AstraZeneca today and set a price target of £115.00.

TipRanks Welcomes a New ETF – NYSE:RANK

• TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
• RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

According to TipRanks, Papadakis is a 4-star analyst with an average return of 3.7% and a 52.42% success rate. Papadakis covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Sanofi.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for AstraZeneca with a p16,126.43 average price target.

Based on AstraZeneca’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of p15.29 billion and a net profit of p3.08 billion. In comparison, last year the company earned a revenue of p13.96 billion and had a net profit of p3 billion

Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AZN in relation to earlier this year.